Disclaimer:
Our content is intended to be used and must be used for information and education purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.
March 15th 2024
An article published in NY times on 3/13/24 titled “A Blood Test Shows Promise for Early Colon Cancer Detection” shared news about a blood test for colon cancer screening.
Let’s look at the results of this ECLIPSE trial published in NEJM:
This blood test missed 87% of advanced precancerous lesions which makes it less useful in early screening. There is also a trend in the data showing the blood test is less effective in detecting early stage cancers (the sensitivity for clinical stage I colorectal cancer was 55% while and sensitivity for clinical stage I, II, or III colorectal cancer was 81%).
While a colonoscope is able to visualize the precancerous polyps and remove them (performing diagnosis and treatment at the same time), the blood test seems to be detecting cancer but at a later stage. If I were the patient I would do the colonoscope. As a physician I would still recommend patients to get a colonoscopy, only when the patient is resistant to the ideas of performing colonoscopy I will recommend for the patient to get a fecal or blood test. Fecal test is more sensitive and more specific partly due to the sample being closer to the tissue (Per Blue-C trial, the next-generation Cologuard test has a sensitivity of 93.9% for colorectal cancer and specificity of 92.7% in a population of asymptomatic adults 40 years of age or older while ECLIPSE trial is conducted in a population of 45 years or old).
Now how much promise does it carry for the trial sponsor Guardant Health? It has to be FDA approved first and be reimbursable by insurance companies and government insurance plans such as Medicaid or Medicare and consumer or primary care physicians have to be willing to order the tests. The current major selling point for Guardant health’s blood based screening test is high patient compliance.
Exact Sciences published a trial in NEJM in 2014: in asymptomatic persons at average risk for colorectal cancer, it detected significantly more cancers than did FIT but had more false positive results. This test is called Cologuard with a cost of $581 to $681. Now 10 years later Cologuard revenue is about 2 billions annually with a trend to grow.
Of notice, Epi ProColon test made by a Germany company Epigenomics AG (FSE: ECX) was approved by FDA but was not granted Medicare payment. It cited the criteria for a blood-based screening test need to have both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to the recognized standard (accepted as colonoscopy at this time).